


## AMENDMENTS TO THE CLAIMS

1 (Currently Amended). A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10 wherein the substituted C<sub>1</sub>-C<sub>6</sub> alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, cyano, SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), OCF<sub>3</sub>, CF<sub>3</sub>, CONH<sub>2</sub>, CON(CH<sub>3</sub>)<sub>2</sub>, or NO<sub>2</sub>;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or indolinyl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-; and

m is a number selected from 1 or 2;

provided that R1 is (substituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10; or

R5 is hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or substituted C<sub>1</sub>-C<sub>6</sub>alkyl; or

R6 and R7 are independently unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl or unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl with the proviso that at least one group is substituted; or


R6 is hydrogen and R7 is substituted C<sub>1</sub>-C<sub>6</sub>alkyl or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl; or

R6 and R7 together with the carbon atom to which they are attached form a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated; or

R8 is substituted C<sub>1</sub>-C<sub>6</sub>alkyl, substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

or a pharmaceutically acceptable salt thereof

2 (Currently Amended) A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C<sub>1</sub>-C<sub>6</sub>alkylNHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or indolinyl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;


R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

3 (Currently Amended). A compound according to claim 1 having Formula I



## Formula I

wherein:

R1 is NHR10 or C<sub>1</sub>-C<sub>6</sub>alkylNHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub>cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or indoliny;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is substituted C<sub>1</sub>-C<sub>6</sub>alkyl, substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;


Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

4 (Previously Presented). A compound according to claim 1 having Formula

I



Formula I

wherein:

R1 is NHR10 or C<sub>1</sub>-C<sub>6</sub>alkylNHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub>cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl) C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or indolinyl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl or unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl with the proviso that at least one group is substituted; or

R6 is hydrogen and R7 is substituted C<sub>1</sub>-C<sub>6</sub>alkyl or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl; or R6 and R7 together with the carbon atom to which they are attached form a substituted C<sub>3</sub>-C<sub>8</sub>cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl,


unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

5 (Currently Amended). A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is (substituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10 wherein the substituted C<sub>1</sub>-C<sub>6</sub> alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, cyano, SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), OCF<sub>3</sub>, CF<sub>3</sub>, CONH<sub>2</sub>, CON(CH<sub>3</sub>)<sub>2</sub>, or NO<sub>2</sub>;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or indolyl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, or unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;


R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group;

Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

6 (Previously Presented). A compound according to claim 2 wherein R1 is




or a pharmaceutically acceptable salt thereof.

7 (Previously Presented). A compound according to claim 6 wherein R6 and R7 are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring; or a pharmaceutically acceptable salt or thereof.

8 (Previously Presented). A compound according to claim 7 wherein R5 is hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

9 (Previously Presented). A compound according to claim 8 wherein R8 is hydrogen, methyl, ethyl or benzyl, or a pharmaceutically acceptable salt thereof.

10 (Previously Presented). A compound according to claim 3 wherein R1 is




or a pharmaceutically acceptable salt thereof.

11 (Previously Presented). A compound according to claim 10 wherein R6 and R7 are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring, or a pharmaceutically acceptable salt thereof.

12 (Previously Presented). A compound according to claim 11 wherein R5 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

13 (Previously Presented). A compound according to claim 12 wherein R8 is C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

14 (Previously Presented). A compound according to claim 4 wherein R1 is



or a pharmaceutically acceptable salt thereof.

15 (Currently Amended). A compound according to claim 14 wherein R6 and R7 are independently C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>2</sub>-C<sub>6</sub>alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C<sub>3</sub>-C<sub>8</sub>cycloalkyl group which is optionally




partly unsaturated and which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

16 (Previously Presented). A compound according to claim 15 wherein R5 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

17 (Previously Presented). A compound according to claim 16 wherein R8 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, benzyl, 1-phenylethyl, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy, methoxy, CONH<sub>2</sub>, or CON(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

18 (Previously Presented). A compound according to claim 5 wherein R1 is selected from -C(CH<sub>3</sub>)(CH<sub>2</sub>OH)NH<sub>2</sub>, -C(CH<sub>2</sub>F)<sub>2</sub>NH<sub>2</sub>, -C(CH<sub>2</sub>F)(CH<sub>2</sub>CH<sub>2</sub>F)NH<sub>2</sub>, -C(CF<sub>3</sub>)(CH<sub>3</sub>)NH<sub>2</sub>, -C(CH<sub>2</sub>CH<sub>2</sub>F)<sub>2</sub>NH<sub>2</sub>, -C(CH<sub>2</sub>CH<sub>3</sub>)(CH<sub>2</sub>CF<sub>3</sub>)NH<sub>2</sub>,



or a pharmaceutically acceptable salt thereof.


19 (Currently Amended). A compound according to claim 18 wherein R6 and R7 are each C<sub>1</sub>-C<sub>3</sub> alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>2</sub>-C<sub>6</sub>alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C<sub>3</sub>-C<sub>8</sub>cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms; or a pharmaceutically acceptable salt thereof.

20 (Previously Presented). A compound according to claim 19 wherein R5 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-

C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

21 (Previously Presented). A compound according to claim 20 wherein R<sub>8</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, benzyl, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

22 (Previously Presented). A compound according to claim 1 having Formula II



Formula II

wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and Q are as defined in claim 1 or a pharmaceutically acceptable salt thereof.

23 (Previously Presented). A compound according to claim 1 wherein R<sub>3</sub> is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl) C<sub>3</sub>-C<sub>8</sub>cycloalkyl; or a pharmaceutically acceptable salt thereof.

24 (Previously Presented). A compound according to claim 23 wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -

OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

25 (Previously Presented). A compound according to claim 1 wherein R<sub>3</sub> is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxy or a pharmaceutically acceptable salt thereof.

26 (Previously Presented). A compound according to claim 1 wherein R<sub>3</sub> is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indolinyl, or (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

27 (Previously Presented). A compound according to claim 1 wherein R<sub>4</sub> is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.


28 (Previously Presented). A compound according to claim 1 wherein R<sub>9</sub> is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

29 (Previously Presented). A compound of according to claim 28 wherein R<sub>9</sub> is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-*t*-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.


30 (Previously Presented). A pharmaceutical formulation comprising one or more compounds according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

31 (Previously Presented). A pharmaceutical formulation according to claim 30 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

32 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula XI or XIb




with a compound of formula XIII



**XIII**


wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in claim 1.

33 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising deprotecting a compound of Formula



wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in claim 1, and PG is an amino protecting group.

34 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula



with a compound of formula XIV

**XIV**

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in claim 1.

35 and 36 (canceled).

37 (Previously Presented). A method of treating a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to an animal in need of said treatment.

38 (Previously Presented). A method of treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to an animal in need of said treatment.

39 (Previously Presented). A compound selected from the group consisting of

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-2-cyclopropylmethyl-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)- 3,3-dimethyl-1,1-dioxo-2-(2-methoxyethyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;


2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2-(2-fluoroethyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2-(4,4,4-trifluorobutyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[2-carbamoylmethyl-5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; and

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-2-(N',N'-dimethylcarbamoyl)methyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;  
or a pharmaceutically acceptable salt thereof.

40 (Previously Presented). A compound of the formula



wherein


X is O, Y is 4-Cl, Z is H and R5 is CH<sub>2</sub>CH<sub>3</sub>; or a pharmaceutically acceptable salt thereof.

41 (Previously Presented). A method for the treatment of a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 39 or a pharmaceutically acceptable salt to an animal in need of said treatment.

43 (Previously Presented). A method c thereof for the treatment of a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 40 or a pharmaceutically acceptable salt to an animal in need of said treatment.

44 (Previously Presented). A method for treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 40 or a pharmaceutically acceptable salt to an animal in need of said treatment.

II



### Formula II

Page 17 of 30



R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 2 or a pharmaceutically acceptable salt thereof.

46 (Previously Presented). A compound according to claim 45 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

47 (Previously Presented). A compound according to claim 45 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxy or a pharmaceutically acceptable salt thereof.


48 (Previously Presented). A compound according to claim 45 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indolinyl, and (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

49 (Previously Presented). A compound according to claim 45 wherein R<sub>9</sub> is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

50 (Previously Presented). A compound of according to claim 49 wherein R<sub>9</sub> is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

51 (Previously Presented). A compound according to claim 3 having Formula

II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 3 or a pharmaceutically acceptable salt thereof.

52 (Previously Presented). A compound according to claim 51 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

53 (Previously Presented). A compound according to claim 51 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxycyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, and 2-methyl thiazolyl;  
or a pharmaceutically acceptable salt thereof.


54 (Previously Presented). A compound according to claim 51 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indolinyl, or (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

55 (Previously Presented). A compound according to claim 51 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

56 (Previously Presented). A compound of according to claim 55 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

57 (Previously Presented). A compound according to claim 4 having Formula

II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 4 or a pharmaceutically acceptable salt thereof.

58 (Previously Presented). A compound according to claim 57 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

59 (Currently Amended). A compound according to claim 57 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxy;


or a pharmaceutically acceptable salt thereof.

60 (Previously Presented). A compound according to claim 57 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indolinyl, or (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

61 (Previously Presented). A compound according to claim 57 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

62 (Previously Presented). A compound of according to claim 61 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

63 (Previously Presented). A compound according to claim 5 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 5 or a pharmaceutically acceptable salt thereof.

64 (Previously Presented). A compound according to claim 63 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

65 (Currently Amended). A compound according to claim 63 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxy;


or a pharmaceutically acceptable salt thereof.

66 (Previously Presented). A compound according to claim 63 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indolinyl, or (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

67 (Previously Presented). A compound according to claim 63 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

68 (Previously Presented). A compound of according to claim 63 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

69 (Previously Presented). A compound according to claim 21 having Formula II



Formula II

wherein



R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 21 or a pharmaceutically acceptable salt thereof.

70 (Previously Presented). A compound according to claim 69 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, or unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

71 (Currently Amended). A compound according to claim 69 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or an unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO<sub>2</sub>Me, trifluoromethyl, and trifluoromethoxy;  
or a pharmaceutically acceptable salt thereof.

72 (Previously Presented). A compound according to claim 69 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, indolyl, indolinyl, or (C<sub>1</sub>-C<sub>6</sub> alkyl) indolyl.

73 (Previously Presented). A compound according to claim 69 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

74 (Previously Presented). A compound of according to claim 69 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.